Gland Pharma receives 2 observations under 483 for Pashamylaram facility

The company is committed to address the observations and will submit its response to US FDA within the stipulated time

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

Granules India successfully completes Two US FDA Audits in a span of 2 weeks

The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society

Elekta Unity MR Linac revolutionizes cancer care in India

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety

USFDA completes inspection at Dr Reddy's Laboratories' Bollaram API unit

The inspection closed with zero observations

International cooperation must to advance vaccine development for emerging pathogens: Health Minister Mandaviya

The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective

NATCO records FY23 PAT at Rs. 715.3 Cr

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.